Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease; ARISE will evaluate the efficacy of solengepr ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...
The presentation entitled, “ Safety and Efficacy Data from a Phase I Trial of Umbilical Lining Stem Cells (ULSCs) in Adult Dermatomyositis/Polymyositis ” was delivered by Michael R Bubb, M.D., ...
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the “Hearings Panel”) has cancelled ...
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...
Il ne faut pas penser qu'une accélération de la croissance osseuse à l'enfance est un effet propice. Car une maturation osseuse précoce peut entraîner unefaiblesse osseuse à l'âge adulte. C'est pourta ...
Cette équipe de la Fujita Health University étudie comment l'hypernatrémie ou un taux de sodium trop élevé dans le sang ...
As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to a final delisting notice sent to the Company by the Listing Qualifications Department ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher ...
Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the “Staff”) ...
In the aggregate, the new non-executive employees received options to purchase 495,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $6.12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback